Leslie Trigg Sells 3,437 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,437 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $4.39, for a total value of $15,088.43. Following the transaction, the chief executive officer directly owned 194,597 shares of the company’s stock, valued at approximately $854,280.83. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Performance

Shares of OM opened at $4.30 on Thursday. The firm has a market cap of $80.84 million, a PE ratio of -1.05 and a beta of 1.96. The stock’s fifty day moving average price is $4.57 and its two-hundred day moving average price is $4.23. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. Outset Medical, Inc. has a 1 year low of $3.00 and a 1 year high of $16.16.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The firm had revenue of $31.64 million for the quarter, compared to analysts’ expectations of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. On average, equities research analysts forecast that Outset Medical, Inc. will post -3.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on OM. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Finally, TD Cowen reissued a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On Outset Medical

Large investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC purchased a new position in shares of Outset Medical in the fourth quarter valued at $29,000. Legal & General Group Plc bought a new position in Outset Medical in the 2nd quarter worth about $34,000. BNP Paribas Financial Markets boosted its stake in Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after purchasing an additional 2,034 shares during the period. Hsbc Holdings PLC purchased a new position in Outset Medical during the 4th quarter valued at about $46,000. Finally, HRT Financial LP purchased a new position in Outset Medical during the 4th quarter valued at about $58,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.